The mission of the Dallas / Fort Worth Resuscitation Outcomes Consortium (DFWROC) is to provide support for clinical trials and research in the areas of heart attack and severe traumatic injury that will change the way paramedics, EMTs, nurses and doctors take care of patients, and save lives.

The focus of all DFWROC research is on pre-hospital and early hospitalization interventions. DFWROC investigators will conduct clinical trials of varying size and duration (for both cardiac arrest and trauma patients), involving pre-hospital and hospital-based healthcare providers.

What's New

June 7, 2018

The ACCESS Trial

Cardiac arrest affects many individuals and is difficult to predict. ACCESS (ACCESS to the cardiac catheterization laboratory in patients resuscitated from out-of-hospital ventricular fibrillation cardiac arrest) is a multi-center study being conducted across the US. The purpose of the ACCESS study is to determine if early cardiac catheterization improves survival.

The results of this study will be published here as they become available.

For additional information, click here.

November 6, 2017

The PART (Pragmatic Airway Resuscitation Trial) is now complete. No additional patients will be enrolled.

The primary objective of the trial was to determine if 72-hour survival after out-of-hospital cardiac arrest (OHCA) is improved with initial endotracheal intubation (ETI) over initial laryngeal tube (LT) airway management strategies.

The results of this study will be published here as they become available.

August 31, 2017

Established Status Epilepticus Treatment Trial (ESETT)

ESETT is an emegency department research study designed to save and improve the lives of people who experience established status epilepticus. This study will look at three commonly used medicines given in emergency departments for established status epilepticus to learn which treatment is most effective at stopping a seizure quickly and safely.

For more information click here

March 13, 2017

The Tranexamic Acid (TXA) study was completed on February 28, 2017.

Over 960 enrolled ROC wide

DFW/ROC enrolled 249

Medstar enrolled 92
Careflite enrolled 74
Dallas fire enrolled 54
Plano fire enrolled 29

Results of this study are pending, and will be posted when they are available.

If you would like more information, please contact the study staff at UT Southwestern Medical Center, 214-648-0408 or email here

Link: Tranexamic Acid (TXA) In Traumatic Brain Injury

October 24, 2015

After enrolling the final patient, the ALPS trial is now officially closed!

All ALPS Kits must be removed from all UTSW/BioTel EMS/Fire apparatus immediately.

The ALPS Kits must NOT be discarded or destroyed – they must be retained for collection and inventory control by ROC Staff over the next several days

Participating “ROC” EMS agencies shall remove from their printed and electronic EMS Treatment Guidelines and other materials all “ROC” versions of EMS Treatment Guidelines for Ventricular Fibrillation and pulseless Ventricular Tachycardia that were distributed to these agencies in 2014.

All patients with recurrent or persistent VF or pVT shall be treated with the standard UTSW/BioTel VF/pVT Guidelines, including defibrillation, epinephrine, and either open-label amiodarone or open-label lidocaine, as specified.

The ROC Team thanks all participants for their hard work and dedication.

July 30, 2015

Dr. Idris held the ROC CTC Steering Committee follow-up meeting July 30th, and presented the 2015 CTC EMS Service Excellence Awards.  To see the list and photos of the award winners, click here.

May 27, 2015

DFW ROC 2015 Excellence Awards

May 27, 2015

The University of Texas Southwestern Medical Center Prehospital Tranexamic Acid Use for Traumatic Brain Injury

Enrollment in this study is expected to begin an August or September of 2015.

More details will be listed here as they become available.

June 10, 2014

2014 ROC Service Excellence Awards

Congrats to Lt. Julius Walker, and Capt. Danny Miller of Dallas Fire-Rescue, Chris Clopton of Carrollton Fire Department, Pam Owens of UT Southwestern, Rhett Daehn of Careflite, Josh Clouse of Plano Fire Department, Anthony Mungioli of Dallas Fire-Rescue,  Amy Yang, and Philip Story of MedStar Ambulance Fort Worthy, who are the 2014 ROC Service Excellence Award winners.

March 11, 2014 - Dr. Ahamed Idris selected by JEMS as one of the top 10 innovators in EMS, who drove the EMS practice forward in 2013 with his work in finding the chest compression "sweet spot" and in measuring what's happening during resuscitation. For the complete list: For more details about what Dr. Idris did and how he did it:

August 22, 2012 - Three years ago 37 year old Mike Nealon and a friend were working out at a gym when Mr. Nealon went into cardiac arrest - he was basically dead.  Today he is alive and well.
Read the full CW33 News article here.

June 26, 2012 - More Texans surviving sudden cardiac arrest. KERA interview with Dr. Ahamed Idris.   Click here

March 17, 2012 - New 5-minute video on how to use the ALPS/CLEARLINK adapter video.   Click here.

December 2011 - ALPS (Amiodarone, Lidocaine Plain Saline)

The goal of ALPS is to determine if survival to hospital discharge is improved with early (and if necessary) repeated therapeutic administration of IV amiodarone compared to no antiarrhythmic drug (plain saline) or lidocaine. It will compare the benefit of what is believed (but as yet unproven) to be the most effective antiarrhythmic drug (amiodarone) against the traditional standard drug (lidocaine) and against neither (plain saline) in shock-resistant cardiac arrest. As such, it will potentially answer 2 critical questions:

(1) Are antiarrhythmic drugs effective for the treatment of VF cardiac arrest?

(2) Is amiodarone preferable to lidocaine for such treatment?

Answering these questions will determine the proven role (if any) of antiarrhythmic drugs for future generations of patients with out-of-hospital cardiac arrest. Antiarrhythmic medications (amiodarone, lidocaine) are frequently used as part of advanced care to treat ventricular arrhythmias that persist or recur during a cardiac arrest. Although much is known about the pharmacological effects of these drugs, there is a considerable gap in knowledge between our understanding of their mechanisms of action and whether their use actually improves survival after cardiac arrest. No pharmacologic agent has ever been demonstrated to improve survival to hospital discharge after cardiac arrest. It is not known whether these drugs may cause more harm than good. The study is being done at 10 locations across the U.S. and Canada. Almost 70 EMS organizations, involving more than 10,000 EMS providers who serve a combined population of nearly 15 million people from diverse urban, suburban and rural regions participate in the ROC Continuous Cardiac Compressions study.  Approximately 3,000 patients will be enrolled at all of the ROC regions in the United States and Canada. The study is expected to last approximately 3 years. The registration number is NCT01401647.

DFWCRR is sponsored by: